PK in Healthy Volunteers

2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 1 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Sanofi
SanofiPARIS, France
1 program
1
FexinidazolePhase 1Small Molecule1 trial
Active Trials
NCT01340157Completed12Est. Apr 2011
PharmaEssentia
PharmaEssentiaMA - Burlington
1 program
1
PEG-MetHuG-CSFPhase 11 trial
Active Trials
NCT06698861CompletedEst. Feb 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
PharmaEssentiaPEG-MetHuG-CSF
SanofiFexinidazole

Clinical Trials (2)

Total enrollment: 12 patients across 2 trials

A Phase I PK/PD Study of PEG-MetHuG-CSF (P2203) in Healthy Volunteers

Start: Aug 2024Est. completion: Feb 2025
Phase 1Completed
NCT01340157SanofiFexinidazole

Fexinidazole (1200mg) Bioavailability Under Different Food Intake Conditions

Start: Feb 2011Est. completion: Apr 201112 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

Small Molecule is the dominant modality (100% of programs)
2 companies competing in this space